Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
trial entities : Exelixis, inc. save search
Exelixis Announces Detailed Results of Phase 3 CONTACT-02 Pivotal Trial Evaluating Cabozantinib in Combination with Atezolizumab in Metastatic Castration-Resistant Prostate Cancer Presented at ASCO GU 2024
Published: 2024-01-25 (Crawled : 22:00) - biospace.com/
TAK | News | $13.16 0.08% 0.15% 2.1K
|
Health Technology
|
| O: -0.27%
H: 0.07%
C: -0.07%
EXEL | $22.495 0.02% 46K
|
Health Technology
|
| O: 0.14%
H: 1.4%
C: -0.23%
ntact-02 asco cancer trial results
Exelixis Announces Initiation of the STELLAR-305 Phase 2/3 Pivotal Trial Evaluating Zanzalintinib in Combination with Pembrolizumab in Patients with Previously Untreated Recurrent or Metastatic Head and Neck Cancer
Published: 2023-12-04 (Crawled : 13:30) - biospace.com/
EXEL | $22.495 0.02% 46K
|
Health Technology
|
| O: -0.46%
H: 2.75%
C: 2.7%
ellar-305 cancer trial
Exelixis Announces Encouraging Results from Expansion Cohort of Phase 1b STELLAR-001 Trial Evaluating Zanzalintinib in Patients with Advanced Kidney Cancer at IKCS 2023
Published: 2023-11-10 (Crawled : 19:00) - biospace.com/
EXEL | $22.495 0.02% 46K
|
Health Technology
|
| O: -0.1%
H: 0.33%
C: 0.0%
ellar-001 kidney cancer expansion trial results
Exelixis Announces Positive Results from Phase 3 CABINET Pivotal Trial Evaluating Cabozantinib in Advanced Pancreatic and Extra-Pancreatic Neuroendocrine Tumors
Published: 2023-08-24 (Crawled : 14:00) - biospace.com/
EXEL | $22.495 0.02% 46K
|
Health Technology
|
| O: 1.15%
H: 0.66%
C: -1.14%
tumors positive pancreatic trial results
Exelixis and Ipsen Announce Positive Results from Phase 3 CONTACT-02 Pivotal Trial Evaluating Cabozantinib in Combination with Atezolizumab in Metastatic Castration-Resistant Prostate Cancer
Published: 2023-08-21 (Crawled : 05:00) - globenewswire.com
TAK | News | $13.16 0.08% 0.15% 2.1K
|
Health Technology
|
| O: -0.4%
H: 0.6%
C: 0.47%
EXEL | $22.495 0.02% 46K
|
Health Technology
|
| O: 0.28%
H: 1.32%
C: 0.99%
ntact-02 positive cancer trial results
Opdivo® (nivolumab) in Combination with CABOMETYX® (cabozantinib) Shows Durable Survival with Over Three Years of Follow-Up in the CheckMate -9ER Trial in First-Line Advanced Renal Cell Carcinoma
Published: 2023-02-13 (Crawled : 00:00) - biospace.com/
TAK | News | $13.16 0.08% 0.15% 2.1K
|
Health Technology
|
| O: -1.37%
H: 0.69%
C: 0.51%
BMY | $48.3 0.96% 0.21% 3.3K
|
Health Technology
|
| O: 0.03%
H: 1.69%
C: 1.32%
EXEL | $22.495 0.02% 46K
|
Health Technology
|
| O: -0.68%
H: 1.66%
C: 1.49%
opdivo renal trial cell carcinoma nivolumab
Exelixis Announces Initiation of the STELLAR-304 Phase 3 Pivotal Trial Evaluating Zanzalintinib in Patients with Advanced Non-Clear Cell Kidney Cancer
Published: 2022-12-22 (Crawled : 14:00) - biospace.com/
EXEL | $22.495 0.02% 46K
|
Health Technology
|
| O: -0.38%
H: 1.37%
C: 1.21%
ellar-304 kidney trial cancer
Exelixis Provides Update on Phase 3 CONTACT-01 Trial Evaluating Cabozantinib in Combination with Atezolizumab in Patients with Metastatic Non-Small Cell Lung Cancer Previously Treated with Immunotherapy and Chemotherapy
Published: 2022-12-08 (Crawled : 22:00) - biospace.com/
TAK | News | $13.16 0.08% 0.15% 2.1K
|
Health Technology
|
| O: -0.07%
H: 1.09%
C: 1.09%
EXEL | $22.495 0.02% 46K
|
Health Technology
|
| O: 0.0%
H: 1.59%
C: 1.04%
ntact-01 lung immunotherapy trial update cancer
Exelixis Announces Initial Dose-Escalation Results from the First-in-Human Phase 1 Trial Evaluating XL102 in Patients with Advanced Solid Tumors at SABCS 2022
Published: 2022-12-08 (Crawled : 14:00) - biospace.com/
EXEL | $22.495 0.02% 46K
|
Health Technology
|
| O: 0.0%
H: 1.59%
C: 1.04%
xl102 sabcs trial tumors results phase 1
Exelixis Announces Promising Initial Dose-Escalation Results from the First-in-Human Phase 1 JEWEL-101 Trial Evaluating XB002 in Patients with Advanced Solid Tumors at ENA 2022
Published: 2022-10-26 (Crawled : 11:00) - biospace.com/
EXEL | $22.495 0.02% 46K
|
Health Technology
|
| O: -0.18%
H: 1.14%
C: -1.8%
jewel-101 xb002 trial tumors results phase 1
Exelixis Announces Cabozantinib in Combination with Nivolumab and Ipilimumab Significantly Improved Progression-Free Survival in Phase 3 COSMIC-313 Pivotal Trial in Patients with Previously Untreated Advanced Kidney Cancer
Published: 2022-07-11 (Crawled : 13:00) - biospace.com/
TAK | News | $13.16 0.08% 0.15% 2.1K
|
Health Technology
|
| O: 0.91%
H: 0.35%
C: -0.21%
EXEL | $22.495 0.02% 46K
|
Health Technology
|
| O: 1.67%
H: 0.0%
C: -5.67%
osmic-313 kidney trial cancer phase 3 nivolumab
Exelixis Announces Initiation of the STELLAR-303 Phase 3 Pivotal Trial Evaluating XL092 in Patients with Metastatic Colorectal Cancer
Published: 2022-06-21 (Crawled : 13:00) - biospace.com/
EXEL | $22.495 0.02% 46K
|
Health Technology
|
| O: 5.5%
H: 0.0%
C: 0.0%
ellar-303 xl092 trial cancer phase 3
Exelixis Announces Detailed Results from Urothelial Carcinoma and Non-Small Cell Lung Cancer Cohorts of the COSMIC-021 Trial at ASCO 2022
Published: 2022-05-26 (Crawled : 00:00) - biospace.com/
TAK | News | $13.16 0.08% 0.15% 2.1K
|
Health Technology
|
| O: -0.17%
H: 0.0%
C: 0.0%
EXEL | $22.495 0.02% 46K
|
Health Technology
|
| O: 0.11%
H: 0.0%
C: 0.0%
osmic-021 trial asco results cancer urothelial carcinoma
Exelixis Announces Initiation of First-In-Human Phase 1 Trial Evaluating XL114 Monotherapy in Patients with Non-Hodgkin’s Lymphoma
Published: 2022-04-14 (Crawled : 13:00) - biospace.com/
EXEL | $22.495 0.02% 46K
|
Health Technology
|
| O: 0.04%
H: 1.26%
C: 0.39%
xl114 trial phase 1
Exelixis Announces Final Overall Survival Results from Phase 3 COSMIC-312 Trial of Cabozantinib in Combination with an Immune Checkpoint Inhibitor in Patients with Previously Untreated Advanced Liver Cancer
Published: 2022-03-14 (Crawled : 01:00) - biospace.com/
TAK | News | $13.16 0.08% 0.15% 2.1K
|
Health Technology
|
| O: 0.42%
H: 0.48%
C: -0.41%
EXEL | $22.495 0.02% 46K
|
Health Technology
|
| O: 0.0%
H: 1.21%
C: -1.91%
osmic-312 liver trial cancer phase 3
Ipsen: Cabometyx® in Combination With Opdivo® Demonstrated Continued Survival and Quality of Life Benefits With Over Two Years of Follow-Up in the Phase III CheckMate -9ER Trial
Published: 2022-02-15 (Crawled : 08:00) - biospace.com/
TAK | News | $13.16 0.08% 0.15% 2.1K
|
Health Technology
|
| O: 0.4%
H: 0.53%
C: 0.46%
EXEL | $22.495 0.02% 46K
|
Health Technology
|
| O: 0.86%
H: 3.36%
C: 2.29%
cabometyx opdivo trial
Opdivo® (nivolumab) in Combination with CABOMETYX® (cabozantinib) Demonstrates Continued Survival Benefits with Over Two Years of Follow-Up in the CheckMate -9ER Trial in First-Line Advanced Renal Cell Carcinoma
Published: 2022-02-14 (Crawled : 23:00) - biospace.com/
TAK | News | $13.16 0.08% 0.15% 2.1K
|
Health Technology
|
| O: 0.27%
H: 0.2%
C: 0.0%
BMY | $48.3 0.96% 0.21% 3.3K
|
Health Technology
|
| O: -0.01%
H: 0.22%
C: -0.09%
EXEL | $22.495 0.02% 46K
|
Health Technology
|
| O: -0.27%
H: 1.12%
C: -0.59%
opdivo renal trial cel cell carcinoma nivolumab
Exelixis Announces Enrollment Completion in Phase 3 CONTACT-03 Pivotal Trial of Cabozantinib in Combination with an Immune Checkpoint Inhibitor in Previously Treated Metastatic Renal Cell Carcinoma
Published: 2022-01-05 (Crawled : 14:30) - biospace.com/
TAK | News | $13.16 0.08% 0.15% 2.1K
|
Health Technology
|
| O: 0.07%
H: 0.8%
C: -1.67%
EXEL | $22.495 0.02% 46K
|
Health Technology
|
| O: -0.43%
H: 1.5%
C: -3.43%
ntact-03 renal trial cel phase 3 enroll cell carcinoma
Exelixis Announces Initiation of Phase 1b Trial Evaluating XL092 in Combination with Immuno-oncology Therapies in Patients with Advanced Solid Tumors
Published: 2021-12-15 (Crawled : 15:00) - biospace.com/
BMY | $48.3 0.96% 0.21% 3.3K
|
Health Technology
|
| O: 0.18%
H: 2.11%
C: 1.66%
NKTR | $1.32 -2.22% -3.85% 11K
|
Health Technology
|
| O: 0.16%
H: 2.52%
C: 2.05%
EXEL | $22.495 0.02% 46K
|
Health Technology
|
| O: -0.59%
H: 5.8%
C: 5.68%
xl092 solid tumors phase 1b trial phase 1 phase 2b
Exelixis Announces Enrollment Completion in Phase 3 CONTACT-01 Pivotal Trial of Cabozantinib in Combination with an Immune Checkpoint Inhibitor in Previously Treated Metastatic Non-Small Cell Lung Cancer
Published: 2021-11-09 (Crawled : 15:15) - biospace.com/
TAK | News | $13.16 0.08% 0.15% 2.1K
|
Health Technology
|
| O: 0.28%
H: 0.0%
C: 0.0%
EXEL | $22.495 0.02% 46K
|
Health Technology
|
| O: -0.69%
H: 0.83%
C: -1.02%
lung cancer cancer phase 3 trial enroll
Gainers vs Losers
| 62% | 38% |
Top 10 Gainers
AGBA | News | $1.4 250.0% 35M
|
Finance
RWOD | $12.0 50.06% 3.9M
|
n/a
INDO | $4.9 20.1% 2.2M
|
Energy Minerals
NURO | $4.32 18.36% 66K
|
Health Technology
HUBC | $1.52 17.83% 4.7M
|
n/a
CARV 4 | $1.77 11.32% 8.5K
|
Finance
BROG | $1.23 10.81% 320K
|
Finance
PARA | $12.03 9.66% 5.8M
|
Information
ADAP | $0.98 9.08% 240K
|
Health Technology
POAI A | $1.25 8.69% 16K
|
Health Technology
Your saved searches
Save your searches and get alerts when important news are released.